What question did this study set out to answer?

This research aims to describe patient characteristics and treatment patterns following pembrolizumab use among early-stage triple-negative breast cancer patients.

February 19, 2026Clinical Cancer Research

Abstract PS5-05-07: Real-world Patient Characteristics and Treatment Patterns with Pembrolizumab Among Patients with Early-Stage Triple-Negative Breast Cancer in the United States

View Full Paper

Ask AI

Bookmark

This research aims to describe patient characteristics and treatment patterns following pembrolizumab use among early-stage triple-negative breast cancer patients.
Retrospective analysis of electronic medical records from August 2021 to July 2023
Examination of previously untreated adults diagnosed with Stage II-III TNBC
Analysis of surgery rates, treatment patterns, and reasons for treatment discontinuation
322 patients were identified with Stage II (61.3%) or Stage III (38.7%) TNBC who underwent definitive surgery
75% of patients in the neoadjuvant setting received pembrolizumab plus chemotherapy
Median time on pembrolizumab in the neoadjuvant and adjuvant settings was 5.3 and 5.6 months respectively

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This retrospective study outlines treatment patterns and characteristics in early-stage TNBC patients, indicating effectiveness of pembrolizumab.

Cite This Study

Haiderali et al. (2026) studied this question.

synapsesocial.com/papers/6996a8b5ecb39a600b3efc6a https://doi.org/10.1158/1557-3265.sabcs25-ps5-05-07

View Full Paper

Ask AI

Bookmark

Implication

This retrospective study outlines treatment patterns and characteristics in early-stage TNBC patients, indicating effectiveness of pembrolizumab.

Abstract PS5-05-07: Real-world Patient Characteristics and Treatment Patterns with Pembrolizumab Among Patients with Early-Stage Triple-Negative Breast Cancer in the United States

Key Points

Discussion

Implication

Cite This Study

Abstract PS5-05-07: Real-world Patient Characteristics and Treatment Patterns with Pembrolizumab Among Patients with Early-Stage Triple-Negative Breast Cancer in the United States

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider